NASDAQ · Drug Manufacturers - Specialty & Generic

Qilian International Holding Group Limited (QLI) Stock

$5.41 -3.57% NASDAQ: QLI Healthcare

Qilian International Holding Group Limited (QLI), founded in 2019 and headquartered in Jiuquan, People's Republic of China, focuses on the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMDs), and a variety of other products. The company's diverse offerings include licorice-derived products such as Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, supplied to pharmaceutical companies for manufacturing traditional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient for producing compound licorice oral solutions.

Valuation

MetricValue
Price$5.41
Market Cap$38.68M
P/E Ratio-24.59
P/B Ratio4.52
P/S Ratio0.83
EPS (TTM)$-0.22
52-Week High$6.69
52-Week Low$1.78
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-16.24%
ROA-15.18%
ROCE-5.85%
Gross Margin1.31%
Operating Margin-5.62%
Net Margin-16.74%
Debt/Equity0.01
Current Ratio5.18

Annual Financials (USD)

Metric20192020202120222023
Revenue$46.0M$50.0M$57.0M$65.0M$46.0M
Operating Profit$6.0M$5.0M$2.0M$3.0M$-3.0M
Net Profit$5.0M$5.0M$3.0M$1.0M$-8.0M
EPS$0.15$0.14$0.09$0.03$-0.22
Op Margin13.4%9.6%4.2%5.1%-5.6%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$35.0M$48.0M$75.0M$65.0M$51.0M
Total Liabilities$13.0M$19.0M$19.0M$10.0M$7.0M
Cash$5.0M$12.0M$10.0M$14.0M$7.0M
Borrowings$5.0M$8.0M$8.0M$2.0M$1.0M

Latest News

HIGH LINER FOODS REPORTS OPERATING RESULTS FOR THE SECOND QUARTER OF 2026 CNW Group · Aug 13, 2026 Harmonic to Participate in Upcoming Investor Conferences PR Newswire · Aug 13, 2026 Macquarie, Westpac to testify in KPMG Australia audit scandal probe Reuters · Aug 13, 2026 Social Security calculator Personal Finance Embeddable Content · Aug 13, 2026 True North Commercial REIT Reports Q2-2026 Results CNW Group · Aug 13, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-1.0M$5.0M$0$13.0M$0
Investing Cash Flow$-1.0M$-1.0M$-28.0M$-7.0M$-8.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-1.0M$7.0M$1.0M$2.0M$-8.0M
Free Cash Flow$-1.0M$5.0M$-3.0M$9.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.25
EV / EBITDA-24.93
FCF Yield-8.79%
Quick Ratio4.33
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BNKKBonk, Inc. $1.22 -5.43% -0.08 $9.76M 0.00%
CERCCerecor Inc. $2.93 -1.68% -0.53 $38.63M 0.00%
EYENEyenovia, Inc. $7.56 +3.99% -1.14 $38.59M 0.00%
HEXOHEXO Corp. $0.71 +2.45% -0.03 $31.24M 0.00%
LUMOLumos Pharma, Inc. $4.34 +0.00% -1.04 $37.54M 0.00%

About Qilian International Holding Group Limited

Qilian International Holding Group Limited (QLI), founded in 2019 and headquartered in Jiuquan, People's Republic of China, focuses on the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMDs), and a variety of other products. The company's diverse offerings include licorice-derived products such as Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, supplied to pharmaceutical companies for manufacturing traditional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient for producing compound licorice oral solutions. QLI also produces Qilian Shan oxytetracycline tablets, used to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and humans, alongside Qilian Shan oxytetracycline APIs for other pharmaceutical manufacturers. Its TCMD line features Ahan antibacterial paste, designed for addressing stubborn chronic skin ailments. Furthermore, the company provides heparin sodium preparations to pharmaceutical firms for developing medications related to cardiovascular diseases, cerebrovascular conditions, and hemodialysis. Beyond the medical sector, Qilian International offers Zhu Xiaochang natural sausage casings for culinary applications. In agriculture, it produces Xiongguan organic fertilizers, formulated to improve crop yield, enhance soil chemical properties, and reduce compaction, as well as Xiongguan organic-inorganic compound fertilizers to stimulate plant growth.

Qilian International Holding Group Limited is headquartered in CN.

Qilian International Holding Group Limited (QLI) stock trades at $5.41 with a market capitalization of $38.68M. The stock is valued at a negative price-to-earnings (P/E) ratio of -24.59, reflecting a net loss over the last twelve months, price-to-book of 4.52, price-to-sales of 0.83. Over the past 52 weeks the stock has ranged between $1.78 and $6.69, and currently trades 19.1% below its 52-week high.

On profitability, Qilian International Holding Group Limited generates a return on equity (ROE) of -16.24% (negative, reflecting a net loss), return on capital employed of -5.85%, an operating margin of -5.62%, a net profit margin of -16.74%.

Official website: www.qlsyy.net

Related Healthcare Stocks

LLY Eli Lilly and Company $1211.40 +3.85% JNJ Johnson & Johnson $253.91 +2.13% ABBV AbbVie Inc. $283.52 +3.34% MRK Merck & Company, Inc. Common Stock (new) $147.37 +3.79% UNH UnitedHealth Group Incorporated Common Stock (DE) $395.62 +4.73% NVS Novartis AG $146.88 +3.14% AZN AstraZeneca PLC $162.03 +3.99% TMO Thermo Fisher Scientific Inc $673.20 +1.53% AMGN Amgen Inc. $426.11 +3.21% GILD Gilead Sciences, Inc. $153.54 +3.80% ABT Abbott Laboratories $102.97 +0.35% NVO Novo Nordisk A/S $38.12 +0.16%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.